Jefferies Has Buy Rating On Optimer Pharm. (OPTR)

Jefferies & Co. has a Buy rating and a $17 price target on shares of Optimer Pharm. OPTR. In a note to clients, Jefferies writes, "As expected, DIFICID (fidaxomicin) gets a positive FDA panel vote for treatment of CDAD (13-0), but the panel votes were mixed on reducing risk of recurrence (potentially new indication) seemingly due to semantics of "recurrence" or "global cure"; while timely approval of fidaxomicin on PDUFA date (5/30/11) is possible, we maintain our conservative approval/launch timeline." Shares of OPTR are down 35 cents in pre-market trading to $13.45.